Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to the Bioventus 2021 Q3 earnings conference call. With me this morning are Ken Reali, CEO, and Greg Anglum, SVP and CFO. Ken will begin with a review of the quarter and the current environment, and then provide an update on our recent acquisitions. Greg will then provide further detail on our third quarter results and update on our 2021 planning outlook. We'll finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, bioventus.com. Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors of the company's Form 10-K for the year ended December 31st 2020, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance upon any forward-looking statements which speak only as of the date that they are made. Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. This call will also include reference to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Definitions and reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investors portion or investor relations portion of our website at www.bioventus.com. Now I'll turn the call over to Ken. Thanks, Dave. Good morning, everyone, and thank you for your interest in Bioventus. As we enter the final months of a transformational year, the outlook for Bioventus has never been more exciting due to the exceptional execution of our growth strategy by our entire team. I'm encouraged by our commercial team's continued performance and resiliency as they delivered another quarter of double-digit organic growth and continue to respond to the challenging dynamics brought on by the pandemic. As we work to integrate Bioness and Misonix, we remain steadfast on returning patients back to their active lifestyle. I will begin my remarks with a review of our results for the quarter before providing an update on our recent acquisitions. Revenue increased 27% for the quarter to $109 million, despite some continued challenges from the pandemic, as we were able to more than offset these headwinds with strong execution across our growth initiatives in other areas of our diversified portfolio. We face some ongoing challenges from the pandemic concentrated in the bone graft substitutes business as elective procedures were interrupted in specific regions of the country during the quarter. As we moved into October, we saw conditions begin to gradually improve, and we currently expect to trend closer to a more normal environment by the end of the Q4. Even with these challenges, we delivered an exceptional quarter of 14% organic growth. In order to give you a better sense of what the growth looked like against our pre-COVID levels, organic growth compared to the Q3 of 2019. Across our three verticals in more detail. Across Pain Treatments, we saw double-digit growth driven by continued share gains for our single injection DUROLANE therapy and our three-injection GELSYN-3 therapy. We remain well positioned to take advantage of the shift towards single and three-injection treatment for osteoarthritic knee pain. DUROLANE, which was the last single injection product launched four years ago, now represents roughly 20% share of the single injection market. Our ability to increase our share is driven by multiple factors. First, our market access strategy of working with private payers is fueling growth as we further augment the strong reimbursement for the therapy. Second, DUROLANE has the highest molecular weight of single injection therapies available, which produces the longest residence time in the joint and an extended half-life. Notably, the American Academy of Orthopaedic Surgeons recently released updated clinical practice guidelines stating certain knee osteoarthritis patients showed statistically significant improvement from high molecular weight treatments. Like DUROLANE, GELSYN-3 represents an opportunity to further expand our share. GELSYN-3 also experienced significant double-digit growth for the quarter and has demonstrated continued share gains. Third, our five-injection therapy, SUPARTZ FX, continues to maintain its leading share position of approximately 40%. While DUROLANE and GELSYN-3 are below the share in their respective categories, there is significant room for additional growth in coming years for both products as they increase penetration in their respective markets. As the only company with a portfolio of HA products across single, three, and five injection therapy, we have now consistently held the number two share position across the entire category and look to become the market leader in the coming years. Turning to our bone graft substitutes vertical, we saw mid-single-digit growth despite the interruption in elective procedures I mentioned earlier. Helping fuel our momentum has been the recent launch of OSTEOAMP SELECT Flowable, our injectable allograft bone graft substitute solution, which can be used for a variety of procedures, including minimally invasive spinal fusions, the fastest-growing area in spine. We are excited by the initial market reaction and feedback from surgeons, and we continue to see bone graft substitutes as a double-digit growth opportunity. Finally, we saw double-digit growth across our Restorative Therapies vertical, bolstered by our advanced rehabilitation products acquired as part of the Bioness acquisition. Additionally, we initiated a pilot to utilize our call point access and sales force to further accelerate Bioness' double-digit growth. The pilot focused on our L300 Go product for patients with gait disturbance, leverages our sales force's relationships with orthopedic surgeons to prescribe the L300 for individuals who receive a total knee replacement but experience thigh muscle weakness during their rehabilitation. Additionally, our legacy EXOGEN business grew mid-single digits organically during the quarter. This performance benefited from growth in our international region, which faced an easier comparison in the Q3, given the impacts of the pandemic in the prior year. Across our international segment, growth of 39% was enhanced by our Bioness acquisition, while organic growth for the quarter was 11%. With close to 10% of our sales coming from international regions, our mix of international sales is below peers. As we introduce new products across various regions and execute against our go-to-market strategy, we expect to see international expansion as a catalyst for future growth in the near and midterm. Now let me update you on our recent acquisitions. In the Q3, Bioness contributed $11 million of revenue and continues to track ahead of our expectations. Revenue was strong across both advanced rehabilitation products and peripheral nerve stimulation, or PNS. The integration of Bioness continues to progress as planned, with several key milestones having been completed. We are realizing planned synergies and reached breakeven profitability at the end of the third quarter. As we look ahead to next year, we have identified specific synergy targets and see Bioness contributing positive EBITDA. Our timeline for full completion of the integration remains the first quarter of 2022. In addition to the financial benefits, Bioness is providing us valuable experience as we prepare to begin the integration of Misonix and look to further develop integration as a core competency of Bioventus. In addition to the L300 Go opportunity I mentioned earlier, we also began a pilot for PNS utilizing our existing sales force. We are encouraged by the initial results, and while a small piece of our portfolio today, we see PNS as a meaningful midterm growth driver for our overall business. Turning to the recently announced closing of our Misonix acquisition, we are excited to welcome the Misonix team to Bioventus and for Stavros Vizirgianakis and Pat Beyer to join our board of directors. I am also pleased to welcome Sharon Klugewicz, who has served as COO of Misonix and will report to me as part of our executive team in the role of Senior Vice President of Quality and Regulatory Affairs. The completed transaction creates a high-growth medical device company with a $15 billion total addressable market and the ability to gain significant market share utilizing our nearly 500-person sales force across our three verticals. The combined business allows us to go deeper with our customers across surgical applications in spinal fusion, neurosurgery, and wound treatments. The deal also furthers our strategy of accelerated revenue growth through acquisitions that leverage our existing infrastructure. We are confident Misonix will drive substantial shareholder value as it is expected to be accretive to our organic growth profile while generating $20 million of cost synergies by the end of 2023. While we were waiting to clear the regulatory hurdles for the acquisition to close, we assembled an internal integration team and coordinated with the leadership at Misonix to develop our integration plan and timeline. We will kick off the integration of Misonix in the Q1. While both Misonix and Bioness provide us with immediate catalyst for growth, our business development activity is also focused on ensuring Bioventus is positioned to maintain double-digit organic growth in the midterm. Last quarter, I spoke to you about the opportunity we were evaluating on whether to preserve our right to exercise our option to purchase CartiHeal. As we announced in late August, after extensive evaluation, we placed $50 million into escrow as a deposit. We plan to finance the remaining portion of the potential acquisition of CartiHeal with additional debt. While there are still steps to take for CartiHeal to gain FDA approval for their Agili-C implant, our due diligence strengthened our belief in the $1.3 billion addressable market opportunity, and that it will be a high quality addition to our portfolio. In coming to our decision, we discussed the merits of Agili-C with over 600 healthcare professionals. In addition, we engaged over a dozen private payers to understand the reimbursement landscape for this unique therapy. Throughout these discussions, there was consistent feedback that Agili-C fills a significant unmet need for surgeons in the treatment of patients with cartilage defects and knee osteoarthritis. Likewise, medical directors of private payers expressed a willingness to support reimbursement for Agili-C based on the strength of the clinical data, which demonstrates superiority to current surgical standard of care. While we are excited about the opportunity for Agili-C to receive FDA approval and to acquire CartiHeal in the second half of next year, we don't expect the acquisition to drive material growth until a few years after launch as private payers steadily begin reimbursing Agili-C. We will continue to provide updates on the status and timing of the potential acquisition as we gather new information on the approval. While M&A remains a meaningful part of our long-term growth strategy and we continue to build new relationships, we are currently highly focused on successfully integrating Bioness and Misonix. In conclusion, we continue to build momentum across our business, execute on our growth strategy, and drive further market penetration with our HA and bone graft substitutes products. I am confident we have enhanced our growth profile with the acquisitions of Bioness and Misonix, and will leverage our commercial infrastructure to deliver consistent double-digit growth while ensuring we deliver on our cost synergies. Now I'll turn the call over to Greg. Thanks, Ken, and let me add how encouraged I am by our team's success in the quarter as we continue to execute in a challenging environment while showing meaningful progress against our growth initiatives throughout the year. Let's begin with a review of our third quarter results. Revenue of $109 million increased 27% compared to last year. We saw a 14 percentage point increase from organic revenue, along with a 13 percentage point benefit related to Bioness. Although hospital utilization was negatively impacted by a new wave of COVID-related hospitalizations during the third quarter, we were able to deliver strong sales as we benefited from our diversified portfolio and the execution of our commercial teams. Our sales performance drove adjusted EBITDA of $21 million and adjusted diluted earnings per share of $0.25. Across pain treatments, we grew 24%, broken down by 21 percentage points of organic growth across our HA portfolio and a three percentage point contribution from our PNS products that we recently acquired from Bioness. PNS revenue grew double digits compared to the prior year under Bioness ownership. As Ken mentioned, we continue to capture market share in our DUROLANE and GELSYN-3 products. Compared to the same period two years ago, DUROLANE revenue has more than doubled in the U.S. and has nearly doubled globally. In bone graft substitutes, revenue was impacted by increased COVID-related hospitalizations that reduced the number of elective procedures. As a result, revenue grew four percent but is up 35% year to date compared to 2020, due in part to the favorable comparison versus prior year, which saw significant impacts from COVID. We estimate the impact from the disruption during the third quarter of this year be approximately $2 million. Excluding this headwind during the quarter, growth would have been double digits consistent with prior quarters. Conditions have begun to gradually improve over the past month. We currently expect to trend closer to a more normal environment by the end of Q4. Finally, across Restorative Therapies, we delivered 52% growth. Organic sales growth from our EXOGEN product was six percentage points, while inorganic growth from sales of the Bioness advanced rehabilitation portfolio was 46 percentage points. Growth in advanced rehabilitation compared to prior year increased double digits. Moving down the income statement, adjusted gross margin of 79% was unchanged compared to last year. While we've experienced some increased transportation costs due to global supply chain challenges, we have offset this through improved manufacturing performance as well as a more favorable product mix. Overall, adjusted operating expenses increased $17 million, driven by costs related to Bioness, public company costs, and a return to more normalized spending patterns when compared to the prior year. In addition, given the strong sales in the first half of the year, we are electing to make some additional strategic investments in the second half to further bolster our growth strategy and build out our corporate capabilities. Now, turning your attention to our bottom-line financial metrics, adjusted EBITDA totaled $21 million compared to $23 million in the prior year. Lower adjusted EBITDA was a result of higher operating costs I just mentioned, partially offset by higher sales volume. Adjusted operating income of $15 million was unchanged compared to last year. Adjusted net income totaled $14 million compared to $13 million a year ago, and we earned $0.25 of adjusted diluted earnings per share. Moving to the balance sheet and cash flow statement. Our balance sheet is solid and continues to provide us with strategic flexibility as we ended the quarter with $81 million of cash on hand and $177 million of debt outstanding. Our revolving credit facility remained undrawn at the end of the third quarter. When factoring in the close of Misonix, which occurred subsequent to quarter end, debt now stands at $376 million and cash on hand is in excess of $50 million. Operating cash flow represented an inflow of $11 million for the quarter. As Ken highlighted, we exercised our option to purchase CartiHeal with a $50 million deposit and made an additional financial investment during the quarter in Trice Medical. We continued to generate strong and consistent cash flow, which provides us with the capability to quickly de-lever when taking on higher debt levels for short periods of time. Finally, let me review our 2021 guidance, which has been updated to reflect the performance of our business in the third quarter, our fourth quarter expectations, and the closing of Misonix. We now expect 2021 revenue to be $425 million-$430 million, an increase from our previous guidance of $405 million-$415 million. The increase in revenue guidance contemplates two months of Misonix revenue following the October 29 closing. Our guidance for adjusted EBITDA is unchanged from previous guidance of $77.8 million-$82.0 million. However, the guidance now reflects stronger than anticipated adjusted EBITDA generated from legacy Bioventus and the Bioness acquisition, offset by the inclusion of Misonix into our guidance. In closing, we continue to execute on our growth initiatives across our business. I'm confident in our ability to maintain our top-line momentum while we complete the integration of Bioness in the coming months and begin to integrate Misonix. Operator, please open the line for questions. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Your first question comes from the line of Kyle Rose from Canaccord. Your line is open. Great. Good morning, everybody, and thank you for taking the question. You know, congrats on a strong quarter here. Wanted to see if we could just touch, you know, first on the pain and joint preservation section here. I'm just wondering, you know, obviously we saw, you know, some surges of the Delta variant, and I realize that that impacted your BGS business. I'm wondering over the course of the last 18 months and, you know, particularly in the Q3, have you seen a benefit there in your pain treatment, just as people might be pushing out, you know, total joint procedures, they might be getting more injections? Is that a dynamic that you're seeing here, or is it really just solely reimbursement access? Yeah, Kyle, good to hear from you. I would say what it's created more than anything with the pandemic is more choppiness as we see ebbs and flows of elective procedures that can create choppiness in their use of hyaluronic acid therapy, for instance. As we've always said, you know, as long as patients feel comfortable going to the doctor's office, and even with the Delta variant that was the case, it was more the elective procedures that were impacted due to hospitalizations of patients with COVID, we're in good shape with that particular product line. From our perspective, you know, it's really not reimbursement driven as much. I mean, our reimbursement strategy certainly aids in our market access strategy more to our market penetration than anything. It really comes down to access to the physicians. We certainly did not see that get curtailed at all in the third quarter. Okay. That's very helpful. You know, you talked about, you know, some, you know, I guess, early initiatives to help drive the Bioness acquisition. You know, I think you talked about, you know, some pilots for using the existing sales force for PNS. I'm just kinda trying to understand, you know, maybe when we should expect to see some of those cross-selling synergies really start to play out into this model. I mean, I understand it's still early days, but maybe just help frame what that cross-selling tailwind should look like in 2022. Sure, Kyle. I mean, starting with peripheral nerve stimulation and our focus as a reminder is on post-surgical pain. We really view products like the StimRouter, our PNS device that we sell today, as being in use in lieu of opioids and prescribing opioids for post-surgical pain control. That initial pilot has gone quite well for us. There is a dedicated PNS team that we inherited from Bioness that does a fantastic job and works with our team in this pilot to generate leads. We do see that expanding to our more broad sales team in 2022. We expect to see increased sales synergies, revenue synergies as we go through 2022. Now, on the L300 Go, our focus, and this is a pilot that just started, is gait disturbance post total knee procedure. These are patients that have a weakened quadricep muscle, which is fairly common, when you have osteoarthritis and you're rehabilitating from a total knee. Their device, the Bioness L300 Go, our device, can restore that gait, through a series of gyroscopes and stimulation of the muscle. This initial pilot we're pretty excited about, because it allows surgeons to prescribe this and get a patient back to walking normally more quickly than they normally would with the aid of the L300 Go. We would expect that pilot to continue here through the end of the year and into the first quarter, but see more significant revenue synergies there as well, probably more in the second half of 2022. Okay, great. Thank you for the additional color here. Thanks, Kyle. Thank you. Your next question comes from the line of Robbie Marcus from JP Morgan. Your line is open. Hey, guys. This is Alan on for Robbie. Just starting off with, you know, the kind of trends that you're seeing and sort of piggybacking off the question asked previously is that, you know, it seems that you guys are definitely holding in a little bit better than some of your other surgical and orthopedic exposed peers. I would guess some of that's based on where you are kind of in the treatment paradigm. Can you just talk about why that might be the case, in your own view, why you're holding up a little bit better, in light of COVID-19 trends in third quarter, why you have so much more confidence in kind of this normalization over the course of 4Q when we're hearing some other peers talk about an extension maybe even into 2022? Yeah, great question, Alan. Look, it starts and ends with our team and our people. We have a resilient, dedicated group at Bioventus, and that goes across our business from our sales team to everyone that supports our sales efforts. That dedication coupled with our strategy translates into what you're seeing today. Now, to peel that back a little further, you know, if we start with our joint pain treatments, our HA products itself, that is normally a first line of defense. As we've talked about, as long as patients feel comfortable going to the doctor's office for treatment, we're in good shape with that therapy. We have excellent reimbursement. We're the only company with a single three and five injection. We've certainly seen the single injection through the pandemic continue to accelerate in usage. We think with our DUROLANE product, which is the highest molecular weight HA product on the market today, we'll continue to see penetration of market share with that product. The product is that good. With GELSYN-3, our three injection, which is still a relatively small percentage of the three injection market, we expect to see continued market share gains there as well. When you look at our other products, we are very diversified and broad. You know, we cut across a large swath of orthopedics. We deal with thousands of orthopedic surgeons on a monthly basis, and that really lends that diversity to the balance and the growth that you consistently see from Bioventus. You know, even with advanced rehabilitation, we have seen terrific things from the Bioness team in that area where their call point is largely post-stroke patients with the gait restoration device I mentioned the pilot, the L300 Go, and that's been a huge success this year. You know, we continue to see good things from EXOGEN. Even with the headwinds with bone graft substitutes, we saw four percent growth when large areas of the country where we're highly penetrated curtailed elective procedures. Once again, that goes down in bone graft substitutes to our strategy of being agnostic to spinal hardware. Being able to work with every spine surgeon no matter what spinal implant they use, and be able to offer a superior product and a very dedicated sales team that sells that product. At the end of the day, as I started out, it comes down to our people, it comes down to our culture, and certainly the ability to execute that type of strategy in a very diversified setting that we have. Got it. I guess just as a quick follow-up, you know, when I look at kind of the Misonix portfolio, it does look like, correct me if I'm wrong, maybe a bit more, you know, interventional in nature. How has that portfolio really held up? I would say that your updated guidance is roughly in line with what we were contemplating for Misonix. Just in terms of the recovery trends for that business and whether or not that's influencing your decision to, you know, start the integration of kind of a quarter late after close. Thank you very much. Yeah, Alan, you know, it's continued to hold up. I would say like a lot of elective procedure-based technologies, it's had some headwinds in certain parts of the country, like we saw with our bone graft substitutes. But that's balanced by their wound business, which is less related to elective procedures. You know, so they're a balanced portfolio as well, having a foot in both elective surgical procedures and spine largely, and then in wound treatments as well. So that team has continued to execute and grow that business. So we're pretty excited about that. And once again, we see tremendous synergies there with our combination in bone graft substitutes, both technologies, the BoneScalpel, as well as our bone graft substitutes, being agnostic to spinal hardware. We see the ability to execute with a combined sales team and penetrate the market more quickly than both companies are doing solo today. With the wound products, we'll continue to sell to the wound centers and the hospitals but add in our office call point there as we go forward with the wound products, where a lot of wounds with the pandemic are being treated in the office, which offers a great opportunity for expansion of their wound business. Our next question comes from the line of Robbie Marcus with J.P. Morgan. Our next question comes from the line of Drew Ranieri with Morgan Stanley. Hi, thanks for taking the questions. I'm sorry if I missed this, but just with Bioness now in the bag, Misonix has closed, just how are you thinking longer term about the growth margin or the growth profile of Bioventus and the margin profile going forward? Look, when we look at opportunities like this, Drew, and thanks for the question. Number one, it has to drive accretive growth, and our goals are consistent double-digit growth in our business. Certainly, we look at both Bioness and Misonix as technologies that have a lot of that growth profile left in them to drive that consistent double-digit growth that is accretive to Bioventus. You know, as far as the margin profile, largely those are in line with what we've done historically. We certainly look at that very carefully when we do any M&A and understand what the margins are, what increased volume can do to impact margins, and certainly what reimbursement looks like as well, and what that can look like in our hands, margin-wise, as we move forward. Both of those areas, accretive growth and margin are critical components, and certainly Bioness and Misonix check both those boxes for us. Got it. Then just on international, I know that it's only roughly 10% of total sales, but growth continues to be strong heading out of international. Can you talk more about some of your initiatives, again, since you've added to the portfolio, maybe go into a little bit more detail about your go to market strategy? And I mean, can you put any framework in place of where international could be in the next 12-24 months as a% of your total sales? Well, as we mentioned, Drew, today it's about 10% of our revenue, and that's below average compared to our peers. Certainly, that's something we think with a broader portfolio with Bioness and now Misonix, we can leverage. We are direct. We have direct sales organizations in Canada, the U.K., and Germany, and a terrific international office in Amsterdam. We think we can leverage those qualities, those attributes, that infrastructure that we have to grow international, hopefully at a faster clip than our double-digit growth. We do see that happening over the course, not just the next twelve to eighteen months, but certainly over the coming three, four, five years. I would see international, I'm not gonna put a prediction out there on the percent of revenue, but I would see it certainly climbing above the 10% that it is today. We see that kind of opportunity, keeping in mind that both Bioness and Misonix did not have direct selling organizations, went through largely distributors. The combination of our direct organizations, our international infrastructure, will allow us, we think, to continue to penetrate markets more fully than both Bioness and Misonix were able to. That certainly will lead to enhanced growth that will probably be above what the total company growth will be. We're pretty excited about that. We also see the APAC region of the world as another opportunity for us, and we'll be looking at that more closely as we go forward and taking advantage of opportunities there as they come forward. Just one last question, just on DUROLANE for a moment. You called out it's the highest molecular weight, and I think coming out of AAOS, there was maybe some positive podium presentations or discussion about high molecular weight HA. But what's been the feedback from clinicians after hearing that data? Are you seeing that in the field? Thank you. Yeah, Drew, it's a net positive. You know, the AAOS comments on HA coming out of the meeting in September were an improvement, we feel, and I think others would agree, over the somewhat tepid attitude towards HA back when they last reviewed this in 2013. Now despite that, the HA business overall has continued to grow at 3%-5%. The fact that DUROLANE is the highest molecular weight, and they certainly correlated strong clinical results with high molecular weight HA. Of course, DUROLANE was not called out, but we know based on our data that is the highest molecular weight, and this is peer-reviewed data. We feel very good about that position. We feel very good about DUROLANE's ability to continue to penetrate the single injection HA market. Keeping in mind it's only been on the market for four years today. It's about 20% of the single injection market, and we think we can double that share over the coming years. If we use SUPARTZ as kind of a predicate for that, which has 40% of the five injection market, we think we can get there with DUROLANE in the years to come. We're very excited about that and certainly the impact it has on patients and their osteoarthritis pain, which continues to be a growing demographic trend. Thank you. I'm showing no further questions. With that, I'll turn the call back over to CEO Ken Reali for any closing remarks. Thank you. Thank you all for your continued interest in Bioventus. While we continue to execute well in this uncertain environment, we remain committed to creating shareholder value. I am confident in our growth strategy and in the ability of our diversified market-leading portfolio to sustain double-digit organic growth while successfully integrating our recent acquisitions. Have a great day.